Trials / Completed
CompletedNCT01502215
Transfusion Requirements in Surgical Oncologic Patient
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 198 (actual)
- Sponsor
- University of Sao Paulo · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Blood transfusion during perioperative period in patients undergoing to major surgery has been associated to several postoperative complications. Particularly in oncologic surgery, red blood cell transfusion has been investigated as a factor of worse outcome and cancer recurrence due to postoperative impairment of cellular immunity. Although red blood cell transfusion has decreased in worldwide clinical practice, this issue still remains a matter of controversy in oncologic surgery. There are no prospective studies comparing outcomes between restrictive or liberal of blood transfusion strategy in oncologic surgery. This study is a prospective and randomized study comparing clinical outcomes between two strategies of transfusion in oncologic surgery - liberal or restrictive
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Red blood cell transfusion | Red blood cell (RBC) transfusion will be given when hemoglobin fall below 9 g/dL since ICU admission until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hemoglobin levels is performed;if a patient's hemoglobin is 9 g/dL or higher, no additional transfusion is necessary. |
| OTHER | Red blood cell transfusion | Red blood cell (RBC) transfusion will be only given when hemoglobin fall below 7 g/dL since ICU admission until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hematocrit is performed;if a patient's hemoglobin 7 g/dL or higher, no additional transfusion is necessary |
Timeline
- Start date
- 2012-01-01
- Primary completion
- 2012-10-01
- Completion
- 2012-12-01
- First posted
- 2011-12-30
- Last updated
- 2012-12-05
Locations
1 site across 1 country: Brazil
Source: ClinicalTrials.gov record NCT01502215. Inclusion in this directory is not an endorsement.